Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Non-Interventional Study.
- Who it may be relevant to
- Registry conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.
Detailed description
PRIMARY OBJECTIVES:
I. Generate induced pluripotent stem cells (iPSC's) from patients receiving cancer treatment.
II. Differentiate patient iPSC's into cardiomyocytes and/or neurons or other cell types that may be relevant to modeling cancer therapy-related adverse effects, such as cardiotoxicity and neurotoxicity.
III. Use patient specific iPSC-derived cells to:
IIIa. Model cancer therapy-related toxicities; IIIb. Better understand the mechanisms of toxicities; IIIc. Determine if patient specific genetic variants are causative of toxicities; IIId. Screen novel protective therapies for cancer therapy-related toxicities.
OUTLINE: This is an observational study.
Patients undergo blood sample collection and have their medical records reviewed on study.
Interventions
- Other Non-Interventional Study
Non-interventional study
Primary outcome measures
- In vitro measurement of cellular viability in response to chemotherapy [Time frame: Blood drawn at enrollment to obtain sample]
Eligibility criteria
Inclusion criteria
- Any patient >= 18 years of age
- Previously treated, planned or currently receiving any potentially toxic cancer therapy including but not limited to chemotherapy, targeted and immunotherapies
Exclusion criteria
- Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
United States · 1 center
- Mayo Clinic in Florida — Jacksonville
Identifiers
NCT: NCT06640010 · MC240101 · 24-002830